journal article·2017-07-04

Evaluation and study of antimicrobial activity of nanoliposomal meropenem against Pseudomonas aeruginosa isolates

Momeni-Javid Zahra, Hamishekar Hamed, Rahmati-Yamchi Mohammad, Zarghami Nosratollah, Abolfazl Akbarzadeh, Milani Morteza

Publisher page

Abstract

BACKGROUND: The aim of this study was to evaluate the antimicrobial efficacy of liposomal meropenem formulation against clinical and laboratory isolates of Pseudomonas aeruginosa. P. aeruginosa isolates were used to determine the MIC and MBC of free and liposomal meropenem. As well as the effect of free and liposomes meropenem compare the minimum biofilm eradication concentration and inhibition of P. aeruginosa motility was assessed. RESULTS: In this study, the MICs and MBC of liposomal meropenem was more effective against all clinical and laboratory strains were significantly lower than those of free meropenem (6.25 μg/ml vs 100 μg/ml). Furthermore, liposomal meropenem (≥1.5 μg/ml) completely eradicated biofilm in all P. aeruginosa isolates. While the free form of drug could eradicate biofilm formation in most of isolates in ≥6.25 μg/ml concentration. In addition, lower concentrations of liposomal meropenem could inhibit the bacterial motility. CONCLUSION: The results clearly indicate that the liposomal formulation of drug is more effective than meropenem alone against antibiotic resistant P. aeruginosa isolates.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Antibiotics Pharmacokinetics and Efficacy · Antibiotic Resistance in Bacteria · Bacterial biofilms and quorum sensing

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Medical Biotechnology, Faculty of Advanced Medical Science, Tabriz University of Medical Science, Tabriz, Iran;

Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran;

Liver and Gastrointestinal Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

References (18)

Show source-provided references
1. 10.1016/j.ijantimicag.2005.10.00710.1016/j.ijantimicag.2005.10.007 ↗
2. Agarwal G · Natl Med J India · 2005 · 18 · 184
3. 10.1517/17425247.2013.82286010.1517/17425247.2013.822860 ↗
4. 10.3109/21691401.2014.97523710.3109/21691401.2014.975237 ↗
5. 10.1080/08927014.2013.81629910.1080/08927014.2013.816299 ↗
6. 10.3109/21691401.2014.95363310.3109/21691401.2014.953633 ↗
7. 10.1080/0036554031000010210.1080/00365540310000102 ↗
8. 10.2478/s11658-006-0030-610.2478/s11658-006-0030-6 ↗
9. 10.2174/15701800778462004010.2174/157018007784620040 ↗
10. 10.1093/jac/dkn42210.1093/jac/dkn422 ↗
11. 10.1556/AMicr.57.2010.3.810.1556/AMicr.57.2010.3.8 ↗
12. 10.1016/j.jksus.2014.12.00710.1016/j.jksus.2014.12.007 ↗
13. 10.1128/AAC.44.10.2869-2872.200010.1128/AAC.44.10.2869-2872.2000 ↗
14. 10.1128/CMR.00040-0910.1128/CMR.00040-09 ↗
15. 10.1016/j.ijpharm.2005.10.00510.1016/j.ijpharm.2005.10.005 ↗
16. 10.1016/j.addr.2005.04.00710.1016/j.addr.2005.04.007 ↗
17. Wikler MA. Performance standards for antimicrobial susceptibility testing: eighteenth informational supplement. 2008: Clinical and Laboratory Standards Institute (CLSI).
18. 10.1378/chest.125.2_suppl.62S10.1378/chest.125.2_suppl.62S ↗